[A21-162] Lenvatinib (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 07.07.2022
Project no.:
A21-162
Commission:
Commission awarded on 14.12.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with advanced or recurrent endometrial cancer whose disease has progressed during or after prior platinum-based chemotherapy at any stage of the disease, when surgery or radiation to cure the cancer is not an option for them
- Patients for whom doxorubicin or paclitaxel is the suitable therapy according to physician’s choice: indication of a considerable added benefit
- Patients for whom a therapy option other than doxorubicin or paclitaxel is the suitable therapy according to physician’s choice: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-160 | Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-122 | Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-19 | Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-57 | Lenvatinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-63 | Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G15-06 | Lenvatinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment) | Commission completed |
| A22-57 | Lenvatinib (endometrial carcinoma) - Addendum to Commission A21-162 | Commission completed |
Federal Joint Committee (G-BA)
2022-07-07 A G-BA decision was published.